EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs

Michela Polici, Damiano Caruso, Benedetta Masci iD, Matteo Marasco iD, Daniela Valanzuolo, Elisabetta Dell'Unto, Marta Zerunian, Davide Campana, Domenico De Santis, Giuseppe Lamberti iD, Elsa Iannicelli, Daniela Prosperi und 4 weitere

Journal of Neuroendocrinology · 2025

DOI: 10.1111/jne.13472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, 2025. Verfasst von Michela Polici und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical-Surgical Sciences and Translational Medicine, ENETS Center of Excellence, Radiology Unit, Sant'Andrea University Hospital, Sapi…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Intestinal Neoplasms, Somatostatin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Open access publishing facilitated by Universita degli Studi di Roma La Sapienza, as part of the Wiley-CRUI-CARE agreement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate a radiomic strategy for predicting progression in advanced gastroenteropancreatic neuroendocrine tumor (GEP‐NET) patients treated with somatostatin analogs (SSAs). Fifty‐eight patients with GEP‐NETs and liver metastases, with baseline computerized tomography (CT) scans from June 2013 to November 2020, were studied retrospectively. Data collected included progression‐free survival (PFS), overall survival (OS), tumor grading, death, and Ki67 index. Patients were categorized into progressive and non‐progressive groups. Two radiologists performed 3D liver segmentation on baseline CT scans using 3DSlicer v4.10.2. One hundred six radiomic features were extracted and analyzed ( T ‐test or Mann–Whitney). Radiomic feature efficacy was evaluated via receiver operating characteristic curves, and both univariate and multivariate logistic regression were used to develop predictive models. A significance level of p < .05 was maintained. Of 55 patients, 38 were progressive (median PFS and OS: 14 and 34 months, respectively), and 17 were non‐progressive (median PFS and OS: 58 months each). Six radiomic features significantly differed between groups ( p < .05), with an area under the curve (AUC) range of 0.64–0.74. Ki67 was the only clinical parameter significantly associated with progression risk (odds ratio (OR) = 1.14, p < .05). The combined radiomic features and Ki67 model proved most effective, showing an AUC of 0.814 ( p = .008). The radiomic model alone did not reach statistical significance ( p = .07). A combined model incorporating radiomic features and the Ki67 index effectively predicts disease progression in GEP‐NET patients eligible for SSA treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsIntestinal NeoplasmsSomatostatinStomach NeoplasmsLiver NeoplasmsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTomography, X-Ray ComputedAdultDisease ProgressionProgression-Free SurvivalRadiomics

Stichwörter der Autor:innen

lanreotideneuroendocrine tumorsoctreotideprognosisradiomic

Substanzen

Somatostatin

Autor:innen und Institutionen

  • Department of Medical-Surgical Sciences and Translational Medicine, ENETS Center of Excellence, Radiology Unit, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Department of Medical-Surgical Sciences and Translational Medicine, ENETS Center of Excellence, Digestive Disease Unit, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Medical Oncology Unit, Alma Mater Studiorum-University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • ENETS Center of Excellence, Nuclear Medicine Unit, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.

ORCID-Profile: Benedetta Masci, Matteo Marasco, Giuseppe Lamberti, Francesco Panzuto

Förderung

  • Open access publishing facilitated by Universita degli Studi di Roma La Sapienza, as part of the Wiley-CRUI-CARE agreement

Zitieren

APA

Polici, M., Caruso, D., Masci, B., Marasco, M., Valanzuolo, D., Dell'Unto, E., Zerunian, M., Campana, D., De Santis, D., Lamberti, G., Iannicelli, E., Prosperi, D., Annibale, B., Laghi, A., Panzuto, F., & Rinzivillo, M. (2025). Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13472

Vancouver

Polici M, Caruso D, Masci B, Marasco M, Valanzuolo D, Dell'Unto E, et al. Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs. Journal of Neuroendocrinology. 2025. doi:10.1111/jne.13472

BibTeX
@article{Polici2025,
  author = {Polici, Michela and Caruso, Damiano and Masci, Benedetta and Marasco, Matteo and Valanzuolo, Daniela and Dell'Unto, Elisabetta and Zerunian, Marta and Campana, Davide and De Santis, Domenico and Lamberti, Giuseppe and Iannicelli, Elsa and Prosperi, Daniela and Annibale, Bruno and Laghi, Andrea and Panzuto, Francesco and Rinzivillo, Maria},
  title = {Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs},
  journal = {Journal of Neuroendocrinology},
  year = {2025},
  doi = {10.1111/jne.13472}
}
Kostenlos starten →